Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 12/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412721 | 0.95 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL4411533 | 0.95 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL4411632 | 0.95 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL17651780 | 0.88 | HSD17B1 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL17651814 | 0.88 | HSD17B1 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL5100896 | 0.84 | CHRNB4 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL584790 | 0.83 | HSD17B1 (0.37) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL5104039 | 0.82 | CHRNB4 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL15522569 | 0.80 | BACE1 (0.35) | — | |
| SCHEMBL2337738 | 0.80 | GCGR (0.40) | HSD17B1HSD17B2CYP3A4ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1600766-B1 | ACTIVE OXYGEN SPECIES MEASURING DEVICE | YUASA MAKOTO (JP) | 2019-06-26 | — | — | EP | claimed |
| US-9867800-B2 | Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen | HALLSTAR INNOVATIONS CORP. (US) | 2018-01-16 | — | — | US | claimed |
| US-20150164852-A1 | METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN | HALLSTAR INNOVATIONS CORP. (US) | 2015-06-18 | — | — | US | claimed |
| WO-2014025370-A1 | TRICYCLIC ENERGY QUENCHER COMPOUNDS FOR REDUCING SINGLET OXYGEN GENERATION | HALLSTAR INNOVATIONS CORP. (US) | 2014-02-13 | — | — | WO | claimed |
| US-8298387-B2 | Reactive oxygen species measuring device | YUASA MAKOTO (JP) | 2012-10-30 | — | — | US | claimed |
| WO-2012000610-A1 | COMPLEXES WITH POLYSTYRENE SULFONATE | Universität des Saarlandes (DE) | 2012-01-05 | — | — | WO | claimed |
| US-20110275686-A1 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) | BIOLITEC, INC. | 2011-11-10 | — | — | US | claimed |
| US-20110142948-A1 | Nanoparticle Carrier Systems based on Human Serum Albumin for Photodynamic Therapy | BIOLITEC, INC. | 2011-06-16 | — | — | US | claimed |
| US-20060289313-A1 | Reactive oxygen species measuring device | YUASA MAKOTO | 2006-12-28 | — | — | US | claimed |
| EP-1600766-A1 | ACTIVE OXYGEN SPECIES MEASURING DEVICE | Yuasa, Makoto (JP) | 2005-11-30 | — | — | EP | claimed |
| US-12071498-B2 | Radically polymerizable compositions | Polynt Composites USA, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-11873306-B1 | Nano-sized 5,10,15,20-tetrakis (4-hydroxyphenyl)-porphyrins pd(II) complex for super medicinal applications | King Faisal University (SA) | 2024-01-16 | — | — | US | disclosed |
| EP-2856109-B1 | LIGHTING SYSTEMS AND METHODS OF USING LIGHTING SYSTEMS FOR IN VITRO POTENCY ASSAY FOR PHOTOFRIN | CONCORDIA LABORATORIES INC (BB) | 2023-09-06 | — | — | EP | disclosed |
| US-20230257500-A1 | RADICALLY POLYMERIZABLE COMPOSITIONS | BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) | 2023-08-17 | — | — | US | disclosed |
| US-11518834-B2 | Radically polymerizable compositions | Polynt Composites USA, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | disclosed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5162519-A | Porphyrins and cancer treatment | EFAMOL HOLDINGS PLC (GB) | 1992-11-10 | — | — | US | disclosed |
| US-4992257-A | Dihydroporphyrins and method of treating tumors | EFAMOL HOLDINGS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0337601-A1 | Porphyrins and medicaments for cancer treatment | SCOTIA HOLDINGS PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873306-B1 | Nano-sized 5,10,15,20-tetrakis (4-hydroxyphenyl)-porphyrins pd(II) complex for super medicinal applications | COX15, HMBS, MT-ND5 | HSD17B1 2003/4885HSD17B2 1405/4885CYP3A4 907/4885 |
| US-20150164852-A1 | METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN | NOX3, CBR3, CCR3 | HSD17B1 2184/4885HSD17B2 2303/4885CYP3A4 1491/4885 |
| US-20110275686-A1 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) | MTHFD1, DLD, HPD | HSD17B1 1923/4885HSD17B2 2134/4885CYP3A4 3175/4885 |
| US-20110142948-A1 | Nanoparticle Carrier Systems based on Human Serum Albumin for Photodynamic Therapy | ALB, HPN, TTR | HSD17B1 3835/4885HSD17B2 3784/4885CYP3A4 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.